Funding
Series A · Biotech

Delix Therapeutics raises $70 million Series A

ARTIS Ventures, RA Capital Management and OMX Ventures co-led the September 2021 financing.

By RoundOS Funding desk

Delix Therapeutics announced a $70 million Series A on September 27, 2021, co-led by ARTIS Ventures, RA Capital Management and OMX Ventures. Participants included Apeiron, Bail Capital, Casa Verde Capital, Dolby Family Ventures, Negev Capital, Noetic Fund, Ocama Partners, Palo Santo, Presight Capital, PsyMed Ventures, R2, Re.Mind Capital, Saya Bio, Vertical Venture Partners and WPSS.

The biotechnology company develops non-hallucinogenic compounds intended to promote neural plasticity. The financing supported the development of its neuroplastogen pipeline.

Use of funds

Advance neuroplastogen development and expand pipeline

Funding history

Series A · This round$70M

Sources

  1. Delix Therapeutics financingwsgr.com · Sep 27, 2021

Similar rounds

All Biotech rounds →
Sunlit Seedlings

Sunlit Seedlings measures biodiversity and microbial activity to help organisations assess and redesign ecosystems.

UndisclosedCorporate investment · Nov 13, 2026
Biomatter

Biomatter designs custom enzymes for pharmaceutical, diagnostic, agricultural and industrial applications.

$18MSeries A · Nov 12, 2026
Orakl Oncology

Combines patient-derived tumour organoids, clinical data and AI to help pharmaceutical companies develop cancer treatments.

$34MSeries A · Nov 12, 2026
LABTECHS

LABTECHS develops rapid sterility testing kits and reagents from research at the University of Toyama.

UndisclosedT-CAF investment commitment · Nov 11, 2026

Related